Literature DB >> 27314079

Intersections at the crossroads: Neurofibromatosis type 1, cAMP, sex, and glioma risk.

Joshua B Rubin1.   

Abstract

Cancer predisposition syndromes, particularly neurofibromatosis type 1 (NF1), provide unique vantage points from which to examine the co-contributions of molecular, cellular, and tissue processes to tumor biology. Polymorphisms in adenylate cyclase 8 affect brain tumor risk in NF1 in a sex-specific fashion, illuminating novel interdependencies in brain tumorigenesis.

Entities:  

Keywords:  Adenylate cyclase; Neurofibromatosis 1; cAMP; glioma; sexual dimorphism

Year:  2015        PMID： 27314079      PMCID： PMC4909402          DOI： 10.1080/23723556.2015.1069917

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.

Authors:  Saba Sharif; Meena Upadhyaya; Rosalie Ferner; Elisa Majounie; Andrew Shenton; Michael Baser; Nalin Thakker; D Gareth Evans
Journal:  J Med Genet       Date:  2011-01-28       Impact factor: 6.318

2.  The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Authors:  Nicole M Warrington; Tao Sun; Jingqin Luo; Robert C McKinstry; Patricia C Parkin; Sara Ganzhorn; Debra Spoljaric; Anne C Albers; Amanda Merkelson; Douglas R Stewart; David A Stevenson; David Viskochil; Todd E Druley; Jason T Forys; Karlyne M Reilly; Michael J Fisher; Uri Tabori; Jeffrey C Allen; Joshua D Schiffman; David H Gutmann; Joshua B Rubin
Journal:  Cancer Res       Date:  2014-11-07       Impact factor: 12.701

3.  Treating brain tumors with PDE4 inhibitors.

Authors:  Rajarshi Sengupta; Tao Sun; Nicole M Warrington; Joshua B Rubin
Journal:  Trends Pharmacol Sci       Date:  2011-03-28       Impact factor: 14.819

4.  Arlm1 is a male-specific modifier of astrocytoma resistance on mouse Chr 12.

Authors:  Jessica C Amlin-Van Schaick; Sungjin Kim; Christina DiFabio; Min-Hyung Lee; Karl W Broman; Karlyne M Reilly
Journal:  Neuro Oncol       Date:  2012-01-10       Impact factor: 12.300

5.  Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.

Authors:  Nicole M Warrington; Scott M Gianino; Erin Jackson; Patricia Goldhoff; Joel R Garbow; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

6.  Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo.

Authors:  Lihua Yang; Erin Jackson; B Mark Woerner; Arie Perry; David Piwnica-Worms; Joshua B Rubin
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

7.  Spatiotemporal differences in CXCL12 expression and cyclic AMP underlie the unique pattern of optic glioma growth in neurofibromatosis type 1.

Authors:  Nicole M Warrington; B Mark Woerner; Girish C Daginakatte; Biplab Dasgupta; Arie Perry; David H Gutmann; Joshua B Rubin
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

Review 8.  Neurofibromatosis type 1 - a model for nervous system tumour formation?

Authors:  Joshua B Rubin; David H Gutmann
Journal:  Nat Rev Cancer       Date:  2005-07       Impact factor: 60.716

9.  Cyclic AMP and adenyl cyclase in brain tumors.

Authors:  M A Furman; K Shulman
Journal:  J Neurosurg       Date:  1977-04       Impact factor: 5.115

Review 10.  An integrative view on sex differences in brain tumors.

Authors:  Tao Sun; Anya Plutynski; Stacey Ward; Joshua B Rubin
Journal:  Cell Mol Life Sci       Date:  2015-05-19       Impact factor: 9.261
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.